DEA's PROPOSED 1985 AGGREGATE PRODUCTION QUOTA FOR CODEINE (FOR SALE)
DEA's PROPOSED 1985 AGGREGATE PRODUCTION QUOTA FOR CODEINE (FOR SALE) is 54.05 mil. grams, according to figures published in the Oct. 11 Federal Register. The codeine aggregate production level proposed by the Drug Enforcement Administration (DEA) is 3.0% above the 52.5 mil. gram level approved by DEA in 1984. The agency proposed a decrease, from 3.58 mil. to 3.53 mil. in the aggregate production quota for codeine (for conversion). In the notice, DEA published its proposals for production quotas for Schedule I and Schedule II controlled substances. The agency recommended quota increases for 14 of 35 agents (for list of proposed 1985 production quotas and 1984 quotas, see box below). (FOOTNOTE) Other substances for which DEA proposed increases, include: morphine (for conversion), a 4.7% increase to 58.08 mil. grams; thebaine, up 14.2% to 6.89 mil. grams; morphine (for sale), up 8.8% to 1.14 mil. grams; methadone, up 31.7% to 1.38 mil. grams; and methadone intermediate, up 31.7% to 1.38 mil. grams. The agency explained that in proposing the quotas, it took account of five factors: (1) actual disposals for 1983 and estimates for 1984 and 1985 for each mfr.; (2) projected trends in net disposals; (3) inventory estimates; (4) projected demand; (5) "estimates of change in legitimate medical needs"; (6) "documented diversion." The deadline for comments on the proposed quotas is Nov. 13. Chart omitted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth